At disease progression, the FGFR2 p.F276C mutation was detected by tumor sequencing and the patient was treated with infigratinib, achieving a partial response after 2 months of treatment and maintaining a response for additional 4 months; afterwards new lesions developed and the treatment was discontinued31. Here, FGFR2 is linked to neoplasm.